Human T-cells recognise N-terminally Fmoc-modified peptide

Stuart I. Mannering, Anthony W. Purcell, Margo C. Honeyman, James McCluskey, Leonard C. Harrison

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.

Original languageEnglish
Pages (from-to)3638-3646
Number of pages9
JournalVaccine
Volume21
Issue number25-26
DOIs
Publication statusPublished - 1 Jan 2003
Externally publishedYes

Keywords

  • Fmoc
  • Peptides
  • T lymphocytes

Cite this

Mannering, S. I., Purcell, A. W., Honeyman, M. C., McCluskey, J., & Harrison, L. C. (2003). Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine, 21(25-26), 3638-3646. https://doi.org/10.1016/S0264-410X(03)00402-X
Mannering, Stuart I. ; Purcell, Anthony W. ; Honeyman, Margo C. ; McCluskey, James ; Harrison, Leonard C. / Human T-cells recognise N-terminally Fmoc-modified peptide. In: Vaccine. 2003 ; Vol. 21, No. 25-26. pp. 3638-3646.
@article{9fbeafcf146a46699ccab6fa07b97de2,
title = "Human T-cells recognise N-terminally Fmoc-modified peptide",
abstract = "We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5{\%}) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.",
keywords = "Fmoc, Peptides, T lymphocytes",
author = "Mannering, {Stuart I.} and Purcell, {Anthony W.} and Honeyman, {Margo C.} and James McCluskey and Harrison, {Leonard C.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0264-410X(03)00402-X",
language = "English",
volume = "21",
pages = "3638--3646",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "25-26",

}

Mannering, SI, Purcell, AW, Honeyman, MC, McCluskey, J & Harrison, LC 2003, 'Human T-cells recognise N-terminally Fmoc-modified peptide', Vaccine, vol. 21, no. 25-26, pp. 3638-3646. https://doi.org/10.1016/S0264-410X(03)00402-X

Human T-cells recognise N-terminally Fmoc-modified peptide. / Mannering, Stuart I.; Purcell, Anthony W.; Honeyman, Margo C.; McCluskey, James; Harrison, Leonard C.

In: Vaccine, Vol. 21, No. 25-26, 01.01.2003, p. 3638-3646.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Human T-cells recognise N-terminally Fmoc-modified peptide

AU - Mannering, Stuart I.

AU - Purcell, Anthony W.

AU - Honeyman, Margo C.

AU - McCluskey, James

AU - Harrison, Leonard C.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.

AB - We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.

KW - Fmoc

KW - Peptides

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0242380659&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(03)00402-X

DO - 10.1016/S0264-410X(03)00402-X

M3 - Article

VL - 21

SP - 3638

EP - 3646

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 25-26

ER -

Mannering SI, Purcell AW, Honeyman MC, McCluskey J, Harrison LC. Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine. 2003 Jan 1;21(25-26):3638-3646. https://doi.org/10.1016/S0264-410X(03)00402-X